The Global Challenge of Antimicrobial Resistance (AMR): Surveillance and Prevention Strategies

by

Introduction

One of the most serious global public health threats facing the 21st century is antimicrobial resistance. As microorganisms such as bacteria, viruses, fungi, and parasites continue to evolve, they are becoming more and more resistant to the drugs that should kill them. This phenomenon has serious consequences in terms of mortality rates, prolonged hospitalizations, and elevated healthcare costs. This has made the world realize that the antibiotics, antifungals, and antivirals that were really helpful in revolutionizing medicine are now losing their effectiveness very badly. AMR surveillance and prevention strategies are, therefore, two important links in the fight against AMR. Knowing the process through which resistance originates, spreads, and can be controlled is relevant to taking measures against public health.

How AMR Works and Its Effect on the World

AMR occurs when microorganisms change due to exposure to an antimicrobial agent. These changes allow them to resist the action of medications that would otherwise kill them or slow their growth. AMR is not only a problem in a localized setting; truly, it is a global challenge that knows no borders. On several occasions, the WHO has warned that the disastrous outcome of AMR and, if not taken up as an emergency, situation is leading the world to a post-antibiotic era where common infections and minor injuries are going to kill humankind once again.

Among the major drivers of this crisis are the overuse and misuse of antibiotics in human medicine and agriculture. In particular, in most parts of the world, antibiotics are sold over-the-counter, which contributes to inappropriate use. Even in agriculture, antibiotics are administered not only against the outbreak of certain diseases in sick animals but also as a promoter of growth and to prevent possible diseases, aggravating them further.

AMR has wide ramifications: Resistant infections have higher morbidity and mortality rates. In the case of COVID-19, there have been reports that the patients who suffered secondary bacterial infections were not even susceptible to the antibacterial practices imposed; this was the reason behind its poor outcomes. Candid auris and multidrug-resistant Aspergillus species are resistant pathogenic organisms of significant growing concern in the discipline of fungal infection. These pathogens are highly resistant to treatment and often cause severe complications in immunocompromised patients, particularly those with COVID-19.

Yearwise Publication Trend on “antimicrobial resistance”

Find publication trends on relevant topics

Surveillance strategies for AMR

Surveillance is, therefore, the cornerstone of any strategy against AMR. Functional surveillance systems would track resistance and its spread at its point of origin, providing critical data that would inform public health policy and treatment guidelines. Among others, the types of surveillance systems include clinical surveillance, laboratory-based surveillance, and central surveillance.

Clinical surveillance is the systematic collection of data regarding infection and the outcome of this infection. This allows trends in resistance patterns for different pathogens and across geographies to be understood. For instance, candidemia, a type of bloodstream infection due to Candida species, has seen an increased incidence during the COVID-19 pandemic, especially in corticosteroid-exposed patients. Surveillance in such cases helps to understand the scope of the problem and develop appropriate treatment protocols.

Laboratory-Based Surveillance: Laboratories are a very fundamental part of the detection of resistance. The detection of resistant strains of bacteria, fungi, and viruses from samples obtained from patients is possible in laboratories. For example, advanced laboratory surveillance techniques have allowed for the identification of azole-resistant Aspergillus species in ICU patients. This kind of surveillance is important for the early detection of emerging resistance and timely interventions.

Sentinel Surveillance: Probably, sites such as hospitals and clinics could be selected to collect detailed data on AMR. The sites would be sentinels in that they provide early warning signs for trends in the emerging resistance. This sentinel surveillance has identified Candida auris arising in many regions. It is a pathogen that exhibits high resistance to currently used antifungal agents.

Recent Publications on “antimicrobial resistance”

Find publications on relevant topics

Strategies for preventing AMR

A multifaceted approach to IPC, antimicrobial stewardship, and public education will go a long way in preventing the spread of AMR.

IPC is another key healthcare practice in the reduction of resistant pathogen transmission. This would involve directly observed hand hygiene measures, the use of PPE, and the isolation of patients infected with the resistant pathogen that decreases the diffusion of AMR. Stringent IPC measures have been implemented during the COVID-19 pandemic to control infection spread, including that of resistant organisms.

Antimicrobial Stewardship: This refers to the appropriate use of antimicrobial agents in order to limit selection for resistance. Stewardship programs are designed for the optimization of the treatment of infections using reduced usage of broad-spectrum antibiotics. For example, targeted antifungal therapy on the basis of laboratory results rather than empirical treatment may be helpful in reducing the emergence of resistance in pathogens such as Aspergillus and Candida.

Public Education and Awareness: Educating the general public about the dangers of misusing antibiotics is very essential to fighting AMR. Public health campaigns that impress on all people that antibiotics should be taken only when needed, based on advice by a health professional, and the full course of treatment completed, can help drive down antibiotic misuse.

Research and Development: New antimicrobial agents have to be developed. The pipeline of new antibiotics has been drying up, with fewer drugs approved for use. Research into new drugs, but also into alternative therapies such as bacteriophage therapy, needs to stay ahead of resistant pathogens. In the same way, the development of rapid diagnostic tests will permit the swift identification of the causative pathogen and its resistance profile, thereby offering opportunities for more targeted treatment options.

Conclusion

The challenge that antimicrobial resistance presents to the world is complex, evolving, and calls for coordinated action on several fronts. Surveillance systems that monitor resistance patterns and inform public health interventions are key to follow-up. All strategies aimed at prevention, including the core of IPC, antimicrobial stewardship, and public education, are very important in fighting against resistance spread. It is not the only one, but we must invest in research and development to ensure that we have the tools necessary to fight these resistant pathogens. As new challenges in infectious disease continue to hit the world, most lately through COVID-19, it is clear that now, more than ever, dealing with AMR counts more than ever. Now is the time to act, lest we face a future where simple infections have become untreatable and the huge advances of modern medicine are undone.

References

  1. Egger, M., Bussini, L., Hoenigl, M. and Bartoletti, M., 2022. Prevalence of COVID-19-associated pulmonary aspergillosis: critical review and conclusions. Journal of Fungi, 8(4), p.390.
  2. Rajni, E., Singh, A., Tarai, B., Jain, K., Shankar, R., Pawar, K., Mamoria, V. and Chowdhary, A., 2021, December. A high frequency of Candida auris blood stream infections in coronavirus disease 2019 patients admitted to intensive care units, Northwestern India: a case control study. In Open forum infectious diseases (Vol. 8, No. 12, p. ofab452). US: Oxford University Press.
  3. Seagle, E.E., Jackson, B.R. and Lockhart, S.R., 2021. The landscape of candidemia during the COVID-19 pandemic [manuscript published online ahead of print 18 June 2021]. Clin Infect Dis, 10.
  4. Salazar, F., Bignell, E., Brown, G.D., Cook, P.C. and Warris, A., 2022. Pathogenesis of respiratory viral and fungal coinfections. Clinical Microbiology Reviews, 35(1), pp.e00094-21.
  5. Kayaaslan, B., Eser, F., Kaya Kalem, A., Bilgic, Z., Asilturk, D., Hasanoglu, I., Ayhan, M., Tezer Tekce, Y., Erdem, D., Turan, S. and Mumcuoglu, I., 2021. Characteristics of candidemia in COVID‐19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non‐COVID‐19 patients. Mycoses, 64(9), pp.1083-1091.
  6. Permpalung, N., Chiang, T.P.Y., Massie, A.B., Zhang, S.X., Avery, R.K., Nematollahi, S., Ostrander, D., Segev, D.L. and Marr, K.A., 2022. Coronavirus disease 2019–associated pulmonary aspergillosis in mechanically ventilated patients. Clinical Infectious Diseases, 74(1), pp.83-91.
  7. Arastehfar, A., Carvalho, A., Nguyen, M.H., Hedayati, M.T., Netea, M.G., Perlin, D.S. and Hoenigl, M., 2020. COVID-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions?. Journal of fungi, 6(4), p.211.

Top Experts on “antimicrobial resistance“